$0.31 EPS Expected for BioTelemetry Inc (BEAT) This Quarter

Wall Street analysts expect that BioTelemetry Inc (NASDAQ:BEAT) will report earnings of $0.31 per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for BioTelemetry’s earnings. The highest EPS estimate is $0.31 and the lowest is $0.30. BioTelemetry reported earnings per share of $0.23 in the same quarter last year, which suggests a positive year-over-year growth rate of 34.8%. The company is expected to report its next earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that BioTelemetry will report full-year earnings of $1.26 per share for the current year, with EPS estimates ranging from $1.13 to $1.34. For the next financial year, analysts expect that the company will post earnings of $1.40 per share, with EPS estimates ranging from $1.31 to $1.50. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Wednesday, April 25th. The medical research company reported $0.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.16. The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $91.55 million. BioTelemetry had a positive return on equity of 16.63% and a negative net margin of 3.13%. BioTelemetry’s revenue was up 69.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.16 EPS.

Several research analysts have recently issued reports on BEAT shares. BidaskClub cut BioTelemetry from a “buy” rating to a “hold” rating in a research report on Saturday, March 3rd. Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a research report on Wednesday, April 25th. Benchmark reaffirmed a “buy” rating and set a $46.00 price objective (up from $44.00) on shares of BioTelemetry in a research report on Thursday, April 26th. TheStreet cut BioTelemetry from a “b-” rating to a “c” rating in a research report on Tuesday, March 20th. Finally, Dougherty & Co reaffirmed a “buy” rating and set a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $43.29.

In related news, insider Fred Broadway sold 54,158 shares of the company’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total value of $1,850,578.86. Following the completion of the sale, the insider now directly owns 64,880 shares of the company’s stock, valued at approximately $2,216,949.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Heather C. Getz sold 36,405 shares of the company’s stock in a transaction dated Wednesday, May 2nd. The shares were sold at an average price of $39.62, for a total value of $1,442,366.10. Following the completion of the sale, the vice president now directly owns 80,561 shares of the company’s stock, valued at $3,191,826.82. The disclosure for this sale can be found here. Over the last three months, insiders sold 196,133 shares of company stock valued at $7,430,172. Insiders own 9.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Pitcairn Co. boosted its position in shares of BioTelemetry by 42.7% in the 1st quarter. Pitcairn Co. now owns 9,614 shares of the medical research company’s stock valued at $298,000 after purchasing an additional 2,875 shares during the period. Stifel Financial Corp boosted its position in shares of BioTelemetry by 9.3% in the 1st quarter. Stifel Financial Corp now owns 438,838 shares of the medical research company’s stock valued at $13,667,000 after purchasing an additional 37,365 shares during the period. Sei Investments Co. boosted its position in shares of BioTelemetry by 37.1% in the 1st quarter. Sei Investments Co. now owns 13,663 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 3,699 shares during the period. Russell Investments Group Ltd. boosted its position in shares of BioTelemetry by 67.1% in the 1st quarter. Russell Investments Group Ltd. now owns 800,351 shares of the medical research company’s stock valued at $24,851,000 after purchasing an additional 321,284 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its position in shares of BioTelemetry by 18.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 15,174 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 2,311 shares during the period. 88.06% of the stock is owned by hedge funds and other institutional investors.

Shares of BioTelemetry traded down $1.80, hitting $40.15, on Friday, Marketbeat.com reports. 509,201 shares of the company’s stock were exchanged, compared to its average volume of 410,679. The stock has a market cap of $1.37 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.30 and a beta of 0.81. BioTelemetry has a 1-year low of $23.30 and a 1-year high of $42.36. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.83 and a current ratio of 1.96.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply